Scilex Holding Co
Company Profile
Business description
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Contact
960 San Antonio Road
Palo AltoCA94303
USAT: +1 650 516-4310
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
31
Stocks News & Analysis
stocks
Acquisition a sign of weakness for overvalued ASX share
stocks
3 global ‘buy the dip’ candidates with wide moats
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,120.90 | 34.10 | 0.38% |
CAC 40 | 7,896.93 | 71.69 | 0.92% |
DAX 40 | 23,748.86 | 50.71 | 0.21% |
Dow JONES (US) | 45,829.38 | 4.84 | -0.01% |
FTSE 100 | 9,277.03 | 6.26 | -0.07% |
HKSE | 26,446.56 | 58.40 | 0.22% |
NASDAQ | 22,313.59 | 172.49 | 0.78% |
Nikkei 225 | 44,768.12 | 395.62 | 0.89% |
NZX 50 Index | 13,208.31 | 19.59 | -0.15% |
S&P 500 | 6,608.67 | 24.38 | 0.37% |
S&P/ASX 200 | 8,853.00 | 31.60 | 0.36% |
SSE Composite Index | 3,860.50 | 10.09 | -0.26% |